Colorectal LLM Wiki

Browse
Home / Sources / ASCRS Ch35 - Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Source created 2026-08-25 · updated 2026-08-25
colorectalHIPECCRSperitoneal-diseasetextbookreference

ASCRS Ch35 - Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Chapter 35, "Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy," ASCRS Textbook of Colon and Rectal Surgery, 4th edition. Authors: Valente MA, Moran BJ. Book pp. 605–617 (title page through References). First chapter of Part IV ("Benign and Miscellaneous Conditions" per the textbook's structure, though CRS/HIPEC itself is oncologic).

Textbook reference chapter (not primary literature). Substantially expands the wiki's existing Cytoreductive Surgery and HIPEC page — previously built primarily under an appendiceal-cancer framing (sourced from Hoehn 2021 - Appendiceal Neoplasms and Quénet 2021 - PRODIGE 7 Trial) — with a colorectal-peritoneal-metastases (CPM)-centered framework, resolving that page's own previously-flagged open item about needing broader-than-appendiceal framing.

Peritoneal disease pathophysiology

  • Pseudomyxoma peritonei (PMP): historically estimated incidence of 1/million/year (per Moran's own 2000 guesswork-based NICE application, now globally cited as if evidence-based — a candid methodological caveat from the chapter's own author) — likely undercounts true incidence, now considered 2–4 operable cases/million/year. PMP nearly always arises from a perforated mucinous appendiceal primary; "pseudomyxoma peritonei" was coined by Werth in 1884, Frankel first described an appendiceal-associated case in 1901.
  • The "redistribution phenomenon" (Fig. 35.1–35.2): free-floating tumor cells/mucin in the peritoneal cavity concentrate via three mechanisms — normal peritoneal fluid circulation/ absorption (main absorption sites: under-surface of the diaphragm, particularly right side; the greater/lesser omentum), gravity, and relative sparing of motile organs (small bowel is protected by constant peristalsis, though invasive tumor types like colorectal adenocarcinoma, adhesions, and advanced disease can overcome this protection). Results in disease concentration in the pelvis, paracolic gutters, and "omental cake" (the greater omentum, from its fluid-absorbing function).
  • "Colorectal peritoneal metastases" (CPM) terminology preferred over "carcinomatosis" by this source — "carcinomatosis" implies diffuse, unresectable disease, whereas CPM is meant to convey that resectable peritoneal disease is the basis for CRS/HIPEC case selection (analogous to how "liver metastases" doesn't imply unresectability the way "carcinomatosis" does for the peritoneum).
  • Colorectal-specific differences from PMP: colorectal cancer cells are more invasive than low-grade appendiceal neoplasms and commonly invade small bowel peritoneum/bowel wall — extensive small bowel involvement (Fig. 35.4) is the single most common reason CRS is abandoned as incomplete/infeasible, unlike PMP where small-bowel-sparing debulking is more often achievable.
  • Incidence/risk factors: synchronous CPM in ~7% of patients, metachronous CPM in a further 10–20%. Risk factors for peritoneal dissemination: T4 stage, possible intraluminal stenting of an obstructing tumor, tumor perforation, poor differentiation grade, mucinous histology, and signet ring cell histology.

Peritoneal Cancer Index (PCI) and completeness of cytoreduction

  • PCI (Fig. 35.3, Sugarbaker): the most widely used peritoneal-disease staging system. Divides the abdomen into 13 regions (9 standard abdominopelvic regions + 4 small-bowel regions); each region scored 0–3 by lesion size (LS0 no tumor, LS1 <0.5cm, LS2 0.5–5cm, LS3 >5cm or confluence); total PCI ranges 0–39.
  • "Radiological PCI" and "Laparoscopic PCI": cross-sectional imaging (CT/PET-CT/MRI) and diagnostic laparoscopy can estimate PCI preoperatively, but both underestimate the true laparotomy-determined PCI, especially for low-volume disease (<3–5mm lesions are essentially undetectable by any current noninvasive imaging modality).
  • PCI and survival: a French multicenter retrospective study of 525 CPM patients found significantly different 5-year OS by PCI tier — 44% for PCI <6, 22% for PCI 7–12, 7% for PCI >19 — with postoperative morbidity/mortality also correlating with increasing PCI.
  • PCI in PMP is different: "C" in PCI was designed for cancer, not PMP, which varies from low-grade to high-grade; PCI should not be used to select PMP patients for CRS/HIPEC, because high-PCI PMP is often still amenable to complete cytoreduction and cure, especially at high-volume centers — this corroborates the existing wiki page's finding (from Hoehn's review) that PCI alone did not predict survival in high-grade appendiceal tumors specifically, with completeness of cytoreduction (CC-0) being the stronger predictor.
  • Completeness of Cytoreduction (CC) score: CC-0 = no visible residual macroscopic tumor; CC-1 = residual nodules <2.5mm (still considered complete cytoreduction, including for PMP from LAMN, since intraperitoneal chemotherapy is thought to penetrate tissue 2–5mm); CC-2 = residual tumors 2.5–25mm; CC-3 = residual tumors >25mm or unresectable confluent disease at any site. Complete cytoreduction is not achievable in an estimated ~20% of CPM operations, due to disease volume or distribution.
  • Table 35.1 lists the peritonectomy procedures (right/left parietal, pelvic, right/left diaphragmatic, right/left liver capsulectomy) and corresponding organ resections (greater/lesser omentum, spleen, ovaries/fallopian tubes, uterus, gallbladder, partial/total gastrectomy) that may be required in combination for extensive PMP — paradoxically, the most extensive surgery is often required for the pathologically least aggressive disease (low-grade PMP), whereas biologically more aggressive CPM is less likely to benefit from such extensive combined resections.

HIPEC technique

Performed after complete macroscopic cytoreduction, via open, semi-open, or closed technique (Fig. 35.5). No standard regimen/duration/drug exists for either appendiceal mucinous tumors or CPM; common regimens: mitomycin C 60–90 minutes at 41–43°C (open or closed technique), or oxaliplatin 30 minutes at 43°C (open technique), sometimes with simultaneous IV 5-FU infusion. Hyperthermia itself has anti-tumor effects and enhances several chemotherapy agents. A candid personal-experience note from co-author Moran: heated perfusion also helps restore patient physiology (patients are often hypothermic after a long CRS laparotomy despite active warming), and normalizing body temperature via HIPEC perfusion was observed to reduce reoperation-for-bleeding rates.

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)

Proposed by Reymond and colleagues in 2011 — aerosolized chemotherapy delivered laparoscopically for diffuse low-volume peritoneal disease (carcinomatosis) not amenable to surgical resection. Reports of disease control/ascites palliation in ovarian, gastric, and colorectal carcinomatosis, and peritoneal mesothelioma, with infrequent complications. Research ongoing into a possible neoadjuvant role, converting unresectable to resectable peritoneal metastases in highly selected patients — not yet an established indication.

Evidence base for CRS/HIPEC in CPM

  • Verwaal et al., phase III RCT (first reported 2003, longer follow-up 2008): 105 patients randomized to systemic 5-FU/leucovorin + palliative surgery vs. CRS + mitomycin-C HIPEC. Median 2-year survival significantly higher with CRS/HIPEC (22.2 vs. 12.6 months); patients achieving CC-0 resection had 5-year survival of 45%.
  • Elias et al. 2009, French retrospective: 48 CPM patients with complete cytoreduction + HIPEC (following systemic chemotherapy) vs. 48 matched patients receiving oxaliplatin/irinotecan-based chemotherapy alone — 5-year OS 51% (median 62.7 months) vs. 13% (median 23.9 months).
  • PRODIGE 7 (French multicenter RCT, resectable CPM, complete cytoreduction achieved in all patients, randomized to CRS alone vs. CRS + oxaliplatin-based HIPEC): presented 2018, full publication still awaited at time of this chapter's writing. Median survival was identical in both arms (42 months) — this corroborates, with an updated median-OS figure, the wiki's existing primary-source-backed Quénet 2021 - PRODIGE 7 Trial summary (41.7 vs. 41.2 months) already on the Cytoreductive Surgery and HIPEC page; HIPEC patients had increased complication rates at 90 days with no difference in treatment-related mortality (1.5% both arms). Interpreted as HIPEC offering no additional benefit over CRS alone in this trial, though possible undetected benefits (e.g., "obstruction-free survival," below) are proposed by this chapter's co-author.
  • Suggestion that oxaliplatin may lack effectiveness as an intraperitoneal agent for CPM and that mitomycin C may re-emerge as the preferred intraperitoneal agent, pending further study — consistent with, though not identical to, the wiki's existing note (from a different, appendiceal- focused mitomycin-vs-oxaliplatin RCT) that oxaliplatin had less hematologic toxicity/better QoL for appendiceal MAN specifically; this chapter's concern is efficacy rather than toxicity, and is CPM-specific rather than appendiceal-specific — not a direct contradiction, but a nuance worth flagging (different endpoints, different populations).

Systemic chemotherapy timing (neoadjuvant/adjuvant) around CRS/HIPEC

  • Rationale for perioperative systemic chemotherapy: ~50% of CRS/HIPEC patients develop extraperitoneal recurrence.
  • Adjuvant timing: a retrospective study of 280 CRS/HIPEC-for-CPM patients found no survival difference by timing of systemic chemotherapy (before vs. after CRS/HIPEC). A 2017 systematic review concluded adjuvant systemic chemotherapy may confer a survival benefit, while the role of neoadjuvant therapy remains unclear and in some cases may be associated with reduced overall survival.
  • Neoadjuvant timing: used by some investigators to downstage peritoneal tumor burden and predict favorable tumor biology (analogous to its use before liver metastasis resection — cross-linked to Management of Colorectal Cancer Distant Metastases). A systematic review (Waite et al.) of 7 studies found little evidence favoring neoadjuvant therapy. Passot et al. analyzed 115 CPM patients receiving neoadjuvant chemotherapy: those with a major or complete histopathologic response had significantly improved survival vs. minor/no response — proposed as a new prognostic tool, with clinical experience suggesting neoadjuvant chemo may help select good responders and allow a "trial of time" with re-imaging in borderline-resectable cases.

Prophylactic/proactive CRS and HIPEC in advanced (non-metastatic-yet) cancer

Given the difficulty of detecting low-volume CPM on imaging, and the dependence of CRS/HIPEC outcomes on complete cytoreduction and low PCI, there is growing focus on preventing CPM or catching it early in high-risk patients, rather than only treating established disease. High-risk factors: limited synchronous peritoneal metastases completely resected at primary tumor surgery, isolated synchronous ovarian metastases, primary tumor perforation, pT4 primary tumor, and mucinous primary histology.

Three strategies under evaluation:

  • Proactive approach: high-risk patients undergo CRS (including resection of organs at risk — e.g., omentectomy, bilateral salpingo-oophorectomy in females) combined with HIPEC at the time of primary resection. Under investigation in the Italian Promenade trial (high-risk T3/T4N0 colonic cancer, ≥5mm invasion beyond muscularis propria) and the Spanish HIPECT4 trial (T4a/b colorectal cancer) — both randomize standard resection vs. proactive CRS + mitomycin-C HIPEC.
  • Adjuvant approach: selected patients undergo HIPEC in the immediate or delayed postoperative period after primary resection alone. Under investigation in the Dutch COLOPEC trial (T4/ perforated colon cancer, adjuvant oxaliplatin HIPEC at time of or within 10 days of surgery, vs. adjuvant systemic chemotherapy alone) — initial results showed adjuvant oxaliplatin HIPEC did not improve 18-month peritoneal-metastases-free survival; long-term results awaited. This is a materially more specific/negative finding than the wiki's existing page's brief COLOPEC mention (previously only known secondhand via Hoehn's review as "no benefit... peritoneal-metastasis-free survival at 18 months unchanged" — now independently corroborated by this chapter with matching detail).
  • Second-look approach: selected patients undergo systematic second-look surgery 6 months–1 year after primary resection, with cytoreduction of any observed peritoneal disease plus HIPEC. Elias et al. 2011 published a second-look series of 41 patients (recruited for resected synchronous minimal CPM, synchronous ovarian metastases, or primary tumor perforation) — 21/41 (56%) had peritoneal metastases found at second-look, all 41 received oxaliplatin-based HIPEC; 5-year OS/DFS 90%/44%. This informed the French ProphyloChip trial (high-risk patients randomized after clear surveillance to ongoing surveillance vs. second-look laparotomy + HIPEC) — initial results showed no difference in 3-year DFS (the primary endpoint); full published details awaited.

Synchronous peritoneal + other-site (liver/lung) oligometastases

Patients with metastases to both the peritoneum and other sites (liver, lung) were traditionally excluded from CRS/HIPEC candidacy given concern about systemic disease progression negating local control efforts. More recent evidence supports combining CRS/HIPEC with limited liver resection in carefully selected patients — Elias and colleagues (2006) reported good outcomes in a small series of synchronous liver + peritoneal CRC metastases; two systematic reviews support this strategy in highly selected cases. General recommendation: patients with up to 3 resectable liver metastases and low PCI (<10) may benefit from combined resection, with some cured. Comparable principles (treatable oligometastatic lung disease via surgical excision or ablation) apply by extension/ personal experience, though little has been formally published on lung-metastasis-plus-CPM treatment strategies specifically. Cross-linked to the liver/lung metastasis detail on Management of Colorectal Cancer Distant Metastases, which does not itself address the peritoneal-metastasis combination.

Palliative CRS for CPM

Complete tumor removal is a prerequisite for CRS/HIPEC benefit — "tumor debulking" (incomplete cytoreduction with palliative intent) generally is outweighed by its morbidity/mortality/QoL impairment, and systemic chemotherapy plus best supportive care is preferred when complete cytoreduction cannot be achieved. Exception: female patients with large ovarian CPM metastases, where progression is common despite systemic chemotherapy (ovarian metastases can be a sanctuary site from systemic drugs) — palliative surgery may be appropriate here. Co-author Moran has proposed "obstruction-free survival" as an outcome measure for advanced CPM management, based on clinical experience and some experimental evidence that HIPEC (even without a proven OS benefit, per PRODIGE 7) might prolong the interval before recurrent obstruction — a hypothesis-generating concept, not established evidence.

Open items / gaps

  • PRODIGE 7's peer-reviewed full publication is separately already independently ingested on the wiki as Quénet 2021 - PRODIGE 7 Trial — this chapter's account (presented 2018, "peer-reviewed full publication awaited") reflects the chapter's writing timepoint, predating that later full publication; no discrepancy, just a temporal snapshot difference.
  • Verwaal (2003/2008), Elias 2009, COLOPEC, Promenade, HIPECT4, and ProphyloChip are not independently ingested as primary literature — all captured only via this textbook chapter's narrative summary.
  • The oxaliplatin-efficacy concern raised here (vs. the appendiceal-specific oxaliplatin-tolerability finding already on the wiki) reflects different endpoints (efficacy vs. toxicity/QoL) in different populations (CPM vs. appendiceal MAN) — flagged as a nuance, not adjudicated.